Cerus Corporation Submits the First of Three Modules in the Premarket Approval (PMA) Application Process for INTERCEPT Platelets
Published: Oct 01, 2013
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has submitted the first of three modules for its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA), for review of the INTERCEPT Blood System for platelets.
Help employers find you! Check out all the jobs and post your resume.